SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that Mr. Jeremy Hayden has been appointed as General Counsel and VP of Business Development. In addition to extensive legal experience in the life sciences industry, Mr. Hayden also has specific expertise in business development, with a lead role in structuring and negotiation of equity and debt financings, mergers and acquisitions, partnerships and collaborations, and inbound and outbound licensing arrangements.
"Cytori has very unique technology and a remarkable therapeutic pipeline that is weighted toward later stage clinical trials"
"Jeremy possesses a deep and broad knowledge of the life sciences including both the pharmaceuticals and medical device sectors," said Dr. Marc Hedrick, President and Chief Executive Officer of Cytori. "This knowledge, combined with his extensive industry deal experience and his experience with FDA and other regulatory bodies will be a valuable resource as we move forward with our product development and commercial expansion on a worldwide basis."
"Cytori has very unique technology and a remarkable therapeutic pipeline that is weighted toward later stage clinical trials," said Mr. Hayden. "Besides supporting the governance and compliance functions of the company, I believe I can contribute immediately to the achievement of the business development goals of the Company. Partnering was an important part of our strategy at my previous company and I feel I can bring some of that knowledge and expertise to Cytori."
Mr. Hayden joins Cytori from Volcano Corporation, where he served as Assistant General Counsel and, among other responsibilities, served as legal business partner to Volcano's business units and supported Volcano's SEC and M&A activities, including Volcano's merger with Royal Philips. Prior to his tenure at Volcano, Mr. Hayden was counsel at several legal firms, including McKenna Long & Aldridge, LLP and Mintz Levin Cohn Ferris Glovsky & Popeo, P.C., during which he advised public and private clients on a broad variety of transactions, including strategic growth, equity and debt investments and acquisitions.
Mr. Hayden earned his J.D. from the University of Michigan Law School and an A.B. in politics from Princeton University.
About Cytori Therapeutics, Inc.
Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori's proprietary technologies and products. For more information: visit www.cytori.com.
Cytori Therapeutics, Inc.
Tiago Girao, 1.858.458.0900